Biologics in Severe Asthma: a State-of-the-art Review

Overview

Journal Eur Respir Rev

Date 2025 Jan 8

PMID 39778920

Authors

Bishal Gyawali

Steve N Georas

Sandhya Khurana

Affiliations

Soon will be listed here.

Abstract

Asthma is considered severe if it remains uncontrolled despite optimal conventional therapy, characterised by poor symptom control, frequent exacerbations and increased exposure to systemic corticosteroids. This has a significant impact on morbidity, mortality and healthcare resource utilisation. Recent advances in the understanding of asthma heterogeneity and immunopathogenesis have helped delineate precise disease pathways. The discovery of these pivotal pathways has led to the development of highly effective biologic therapies. Currently available asthma biologics target immunoglobulin E, interleukin (IL)-5/IL-5Rα, IL-4Rα and thymic stromal lymphopoietin. Identification of specific asthma phenotypes, utilising easily measurable biomarkers, has paved the way towards personalised and precision asthma management. Biologic therapies play a significant role in reducing exacerbations, hospitalisations and the need for maintenance systemic steroids, while also improving the quality of life in patients with severe asthma. The evidence for their clinical efficacy comes from randomised controlled trials (RCTs), extension studies, metanalyses and real-world data. This review synthesises findings from early, pivotal RCTs and subsequent studies following the approval of biologics for severe asthma. The safety and efficacy data from these studies, completed in a variety of settings, provide practical perspectives on their application and enhance their generalisability.

References

McGregor M, Krings J, Nair P, Castro M . Role of Biologics in Asthma. Am J Respir Crit Care Med. 2018; 199(4):433-445. PMC: 6835092. DOI: 10.1164/rccm.201810-1944CI. View

Alhossan A, Lee C, MacDonald K, Abraham I . "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. J Allergy Clin Immunol Pract. 2017; 5(5):1362-1370.e2. DOI: 10.1016/j.jaip.2017.02.002. View

Korn S, Bourdin A, Chupp G, Cosio B, Arbetter D, Shah M . Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J Allergy Clin Immunol Pract. 2021; 9(12):4381-4392.e4. DOI: 10.1016/j.jaip.2021.07.058. View

Sverrild A, Hansen S, Hvidtfeldt M, Clausson C, Cozzolino O, Cerps S . The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2021; 59(1). DOI: 10.1183/13993003.01296-2021. View

Jackson D, Heaney L, Humbert M, Kent B, Shavit A, Hiljemark L . Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2023; 403(10423):271-281. DOI: 10.1016/S0140-6736(23)02284-5. View

Casale T, Molfino N, Silver J, Bogart M, Packnett E, McMorrow D . Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. Ann Allergy Asthma Immunol. 2021; 127(3):354-362.e2. DOI: 10.1016/j.anai.2021.05.021. View

Hashimoto S, Kroes J, Eger K, Mau Asam P, Hofstee H, Bendien S . Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers. J Allergy Clin Immunol Pract. 2022; 10(8):2099-2108.e6. DOI: 10.1016/j.jaip.2022.04.014. View

Hanania N, Niven R, Chanez P, Antoine D, Pfister P, Conde L . Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organ J. 2022; 15(10):100695. PMC: 9519799. DOI: 10.1016/j.waojou.2022.100695. View

Blaiss M, Bleecker E, Jacob-Nara J, Nair R, Duh M, Wang Z . Real-world effectiveness of dupilumab in patients with asthma: Findings from the US ADVANTAGE study. Ann Allergy Asthma Immunol. 2023; 132(4):463-468.e1. DOI: 10.1016/j.anai.2023.11.006. View

10.

Menzies-Gow A, McBrien C, Unni B, Porsbjerg C, Al-Ahmad M, Ambrose C . Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study. J Asthma Allergy. 2022; 15:63-78. PMC: 8763264. DOI: 10.2147/JAA.S328653. View

11.

Khatri S, Moore W, Gibson P, Leigh R, Bourdin A, Maspero J . Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2018; 143(5):1742-1751.e7. DOI: 10.1016/j.jaci.2018.09.033. View

12.

Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J . Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013; 143(2):398-405. DOI: 10.1378/chest.12-1372. View

13.

FitzGerald J, Bleecker E, Bourdin A, Busse W, Ferguson G, Brooks L . Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma. J Asthma Allergy. 2019; 12:401-413. PMC: 6910092. DOI: 10.2147/JAA.S227170. View

14.

Chen M, Nopsopon T, Akenroye A . Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2023; 11(5):1475-1484.e20. PMC: 10601343. DOI: 10.1016/j.jaip.2022.12.046. View

15.

Chan R, Duraikannu C, Lipworth B . Clinical Associations of Mucus Plugging in Moderate to Severe Asthma. J Allergy Clin Immunol Pract. 2022; 11(1):195-199.e2. DOI: 10.1016/j.jaip.2022.09.008. View

16.

Kavanagh J, dAncona G, Elstad M, Green L, Fernandes M, Thomson L . Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. Chest. 2020; 158(2):491-500. DOI: 10.1016/j.chest.2020.03.042. View

17.

Murphy K, Jacobs J, Bjermer L, Fahrenholz J, Shalit Y, Garin M . Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2017; 5(6):1572-1581.e3. DOI: 10.1016/j.jaip.2017.08.024. View

18.

Mukherjee M, Kjarsgaard M, Radford K, Huang C, Leigh R, Dorscheid D . Omalizumab in patients with severe asthma and persistent sputum eosinophilia. Allergy Asthma Clin Immunol. 2019; 15:21. PMC: 6448265. DOI: 10.1186/s13223-019-0337-2. View

19.

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View

20.

Hanania N, Alpan O, Hamilos D, Condemi J, Reyes-Rivera I, Zhu J . Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011; 154(9):573-82. DOI: 10.7326/0003-4819-154-9-201105030-00002. View